Hereditary angioedema market is estimated to be valued at USD 2.86 Bn in 2024 and is expected to reach USD 5.36 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031.
Discover market dynamics shaping the industry: Request sample copy
The hereditary angioedema market growth is primarily driven by increasing awareness of the condition and the availability of novel treatment options. Enhanced diagnostic technologies have led to more accurate and earlier diagnoses, expanding the patient base and boosting demand for effective therapies. The introduction of oral medications allows for convenient self-administration at home, making them preferable to traditional injectable treatments. However, the market faces significant restraints, particularly the high costs associated with these medications, which can limit accessibility for many patients.
Discover high revenue pocket segments and roadmap to it: Request sample copy
Insights By Type- Rising Awareness Boosts hereditary angioedema Type I Segment Growth
In terms of type, hereditary angioedema type I segment is estimated to contribute the highest market share of 67.3% in 2024, due to increased awareness about the condition. Rising diagnosis rates and awareness initiatives have encouraged patients with mild symptoms to seek treatment. Advancements in targeted therapy have also improved the management of attacks and adherence to treatment protocols.
Insights By Drug Class- C1 Esterase Inhibitor Maintains Dominance Due to Safety Profile
In terms of drug class, C1 esterase inhibitor segment is estimated to contribute the highest market share of 29.6% in 2024, due to its established efficacy and safety profile. It is the first U.S. FDA-approved treatment for acute HAE attacks, enhancing patient adherence through self-administration options. Rapid reconstitution and action of C1 esterase inhibitor within 30 minutes empower patients to manage initial symptoms effectively, solidifying its leading position in the market.
Insights By Route of Administration- Patient convenience drives the subcutaneous segment growth
In terms of route of administration, subcutaneous segment is estimated to contribute the highest market share of 29.6% in 2024, due to its convenience for patients. Self-administered subcutaneous treatments have become increasingly popular among HAE patients, as these eliminate the need for hospital visits, which is particularly beneficial for managing mild-to-moderate attacks away from medical facilities.
To learn more about this report, Request sample copy
Dominating Region- North America
North America is expected to dominate the market, with an estimated market share of 35.8% in 2024. This is due to factors such as the strong presence of leading pharma companies, supportive healthcare reimbursement policies, and higher patient awareness levels.
Fastest-Growing Region- Asia Pacific
Asia Pacific region exhibits the fastest growth, with an estimated market share of 22.4% in 2024, due to rapidly developing healthcare infrastructure, improving access to diagnosis and treatment, and efforts by major players to expand their presence in emerging markets.
Hereditary Angioedema Market Outlook for Key Countries
Launch of innovative therapies in U.S.
The U.S. hereditary angioedema industry growth is driven by launches of innovative therapies. Companies are increasingly investing in clinical trials to develop more targeted treatment protocols, focusing on precision medicine that addresses individual patient needs. This investment is crucial as it leads to the emergence of next-generation therapies, including oral medications and subcutaneous injections, which are designed for greater convenience and improved adherence.
Germany’s favorable national guidelines and funding
Germany hereditary angioedema industry growth is driven by favorable national guidelines and funding aimed at rare disease management. The German government's commitment to improving healthcare for rare diseases is evident in its National Action Plan, which outlines comprehensive strategies to enhance diagnostics, treatment, and patient care. Collaboration between healthcare providers and pharmaceutical companies fosters research and development initiatives that aim to bring new therapies to market.
Japan’s increasing clinical focus
Japan’s increasing clinical focus on HAE drives the market growth. Growing recognition of HAE among healthcare professionals is supported by targeted marketing campaigns aimed at enhancing disease awareness. Pharmaceutical companies are actively engaging in educational initiatives to inform physicians about the symptoms, diagnosis, and treatment options available for HAE. Japan hereditary angioedema market is witnessing significant investments from key players in the development of new therapies tailored for HAE patients.
China’s government's commitment to enhancing medical access and improving healthcare infrastructure
China hereditary angioedema industry growth is driven by the government's commitment to enhancing medical access and improving healthcare infrastructure. The Chinese government has prioritized healthcare reform, aiming to provide universal access to medical services and address the disparities in healthcare availability across urban and rural areas. This focus is part of the broader "Healthy China 2030" initiative, which seeks to improve health outcomes and promote disease prevention.
Get actionable strategies to beat competition: Request sample copy
Top Strategies Followed by Hereditary Angioedema Market Players
Emerging Startups in the Hereditary Angioedema Market
Key Takeaways from Analyst
The global hereditary angioedema market is expected to witness steady growth over the forecast period due to increasing disease awareness and diagnosis rates. The market currently has few approved treatment options and there remains a large unmet need. The launch of novel therapies with improved efficacy and convenience of administration could transform the treatment landscape.
Lack of disease awareness in developing countries may negatively impact the market growth. High unmet needs represent lucrative opportunities for leading pharmaceutical companies to develop novel treatment options and gain more market share. Development of subcutaneous and oral drugs with improved pharmacokinetics will augment patient adherence to treatment.
North America will likely continue dominating the market given the region's high healthcare spending and early adoption of new drugs. However, other developed markets in Europe and Asia Pacific are also expected to see faster growth.
Hereditary Angioedema Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | US$ 2.86 Bn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 9.4% | 2031 Value Projection: | US$ 5.36 Bn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
CSL Behring, Sanofi, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Market Driver- Increasing prevalence of hereditary angioedema
Increasing prevalence of HAE can drive the market growth. For instance, according to an article published by the National Center for Biotechnology Information, in May 2022, the estimated prevalence of HAE is 1 in 50,000 worldwide. According to the National Organization for Rare Disorders (NORD), the risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.
Market Challenge- Missed diagnosis or misdiagnosis
The market growth can be hampered due to factors such as frequent misdiagnosis of the condition. For instance, according to an article published by Everyday Health, Inc., in June 2020, people with HAE are often misdiagnosed as having another medical problem. About 40% of people with HAE are diagnosed within the first three years whereas almost 33% of people still face delays of 10 years or longer.
Market Opportunity - Product pipeline for treatment
Robust product pipeline for HAE treatments presents significant growth opportunities for market players. Companies are developing next-generation prophylactic and on-demand therapies, including oral drugs and subcutaneous injections, which enhance treatment adherence. With compounds like long-acting C1 inhibitors and kallikrein inhibitors, these innovations focus on self-administration and variable dosing, promising to improve the quality of life for HAE patients.
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients